- Home
- KALV vs DEA Comparison
KALV vs DEA Comparison
Compare KALV & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | DEA |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KALV | DEA |
|---|---|---|
| Price | $26.74 | $22.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $32.60 | $23.49 |
| AVG Volume (30 Days) | ★ 4.5M | 296.0K |
| Earning Date | 07-09-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.77% |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | $50,000,000.00 | ★ $336,099,000.00 |
| Revenue This Year | $185.42 | $5.41 |
| Revenue Next Year | $59.23 | $3.33 |
| P/E Ratio | ★ N/A | $1,151.00 |
| Revenue Growth | ★ 495.66 | 11.27 |
| 52 Week Low | $9.83 | $20.56 |
| 52 Week High | $26.85 | $24.94 |
Technical Indicators
Market Signals| Indicator | KALV | DEA |
|---|---|---|
| Relative Strength Index (RSI) | 74.83 | 48.15 |
| Support Level | $14.56 | $20.89 |
| Resistance Level | N/A | $23.88 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 98.60 | 27.73 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.